Clinical trial
A Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine Revaccinations in the Elderly
NCT04701788 is registered in ClinicalTrials.gov with China National Biotec Group Company Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine Revaccinations in the Elderly
- Lead sponsor
- China National Biotec Group Company Limited
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 30, 2021
- Completion date
- February 15, 2022
- Enrollment
- 331 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
vaccination